

- Ganesan, A. The impact of natural products upon modern drug discovery. *Curr. Opin. Chem. Biol.* **2008**, *12*, 306–317.
- Barreiro, G.; Kim, J. T.; Guimarães, C. R. W.; Bailey, C. M.; Domoaal, R. A.; Wang, L.; Anderson, K. S.; Jorgensen, W. L. From docking false-positive to active anti-HIV Agent. *J. Med. Chem.* **2007**, *50*, 5324–5329.
- Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. GLIDE: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *J. Med. Chem.* **2004**, *47*, 1739–1749.
- Leach, A. R.; Hann, M. M.; Burrows, J. N.; Griffen, E. J. Fragment screening: an introduction. *Mol. Biosyst.* **2006**, *2*, 429–446.
- Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery. *J. Med. Chem.* **2008**, *51*, 3661–3680.
- Rodgers, D. W.; Gamblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. *Proc. Natl. Acad. Sci. U.S.A.* **1995**, *92*, 1222–1226.
- Jorgensen, W. L.; Tirado-Rives, J. Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. *Proc. Nat. Acad. Sci. U.S.A.* **2005**, *102*, 6665–6670.
- Jorgensen, W. L.; Ruiz-Caro, J.; Tirado-Rives, J.; Basavapathruni, A.; Anderson, K. S.; Hamilton, A. D. Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 663–667.
- Ruiz-Caro, J.; Basavapathruni, A.; Kim, J. T.; Wang, L.; Bailey, C. M.; Anderson, K. S.; Hamilton, A. D.; Jorgensen, W. L. Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 668–671.
- Thakur, V. V.; Kim, J. T.; Hamilton, A. D.; Bailey, C. M.; Domoaal, R. A.; Wang, L.; Anderson, K. S.; Jorgensen, W. L. Optimization of pyrimidinyl- and triazinyl- amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 5664–5667.
- Kim, J. T.; Hamilton, A. D.; Bailey, C. M.; Domoaal, R. A.; Wang, L.; Anderson, K. S.; Jorgensen, W. L. FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. *J. Am. Chem. Soc.* **2006**, *128*, 15372–15373.
- Jorgensen, W. L. QIKPROP, v 3.0. New York: Schrödinger LLC; **2006**.
- Jorgensen, W. L.; Tirado-Rives, J. Molecular modeling of organic and biomolecular systems using BOSS and MCPRO. *J. Comput. Chem.* **2005**, *26*, 1689–1700.
- Jorgensen, W. L. The many roles of computation in drug discovery. *Science* **2004**, *303*, 1813–1818.
- Kellenberger, E.; Rodrigo, J.; Muller, P.; Rognan, D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. *Proteins* **2004**, *57*, 225–242.
- Leach, A. R.; Shoichet, B. K.; Peishoff, C. E. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. *J. Med. Chem.* **2006**, *49*, 5851–5855.
- Zhou, Z.; Felts, A. K.; Friesner, R. A.; Levy, R. M. Comparative performance of several flexible docking programs and scoring functions: enrichment studies for a diverse set of pharmaceutically relevant targets. *J. Chem. Inf. Model.* **2007**, *47*, 1599–1608.
- Tirado-Rives, J.; Jorgensen, W. L. Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. *J. Med. Chem.* **2006**, *49*, 5880–5884.
- Barreiro, G.; Guimarães, C. R. W.; Tubert-Brohman, I.; Lyons, T. M.; Tirado-Rives, J.; Jorgensen, W. L. Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring. *J. Chem. Info. Model.* **2007**, *47*, 2416–2428.
- Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision GLIDE: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. *J. Med. Chem.* **2006**, *49*, 6177–6196.
- Zeevaart, J. G.; Wang, L.; Thakur, V. V.; Leung, C. S.; Tirado-Rives, J.; Bailey, C. M.; Domoaal, R. A.; Anderson, K. S.; Jorgensen, W. L. Optimization of azoles as anti-HIV agents guided by free-energy calculations. *J. Am. Chem. Soc.* **2008**, *130*, 9492–9499.
- Cournia, Z.; Leng, L.; Gandavadi, S.; Du, X.; Bucala, R.; Jorgensen, W. L. Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. *J. Med. Chem.* **2009**, *52*, 416–424.
- Irwin, J. J.; Shoichet, B. K. ZINC: a free database of commercially available compounds for virtual screening. *J. Chem. Inf. Model.* **2005**, *45*, 177–182.
- Morand, E. F.; Leech, M.; Bernhagen, J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. *Nat. Rev. Drug Discov.* **2006**, *5*, 399–411.
- Hagemann, T.; Robinson, S. C.; Thompson, R. G.; Charles, K.; Kulbe, H.; Balkwill, F. R. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. *Mol. Cancer Ther.* **2007**, *6*, 1993–2002.
- Senter, P. D.; Al-Abed, Y.; Metz, C. N.; Benigni, F.; Mitchell, R. A.; Chesney, J.; Han, J.; Gartner, C. G.; Nelson, S. D.; Todaro, G. J.; Bucala, R. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 144–149.
- Sun, H. W.; Bernhagen, J.; Bucala, R.; Lolis, E. Crystal structure at 2.6-Å resolution of human macrophage migration inhibitory factor. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 5191–5196.
- Egan, W. J.; Merz, K. M., Jr.; Baldwin, J. J. Prediction of drug absorption using multivariate statistics. *J. Med. Chem.* **2000**, *43*, 3867–3877.
- Lipinski, C. A.; Lombardo, E.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* **2001**, *46*, 3–26.
- Jorgensen, W. L.; Duffy, E. M. Prediction of solubility from structure. *Adv. Drug Deliv. Rev.*, *54*, 355–365.
- Norinder, U.; Bergström, C. A. S. Prediction of ADMET properties. *ChemMedChem* **2006**, *1*, 920–937.
- Proudfoot, J. R. The evolution of synthetic oral drug properties. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1087–1090.
- Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. *J. Med. Chem.* **2004**, *47*, 550–557.
- Chipot, C.; Pohorille, A. In *Springer Series in Chemical Physics: Free Energy Calculations: Theory and Applications in Chemistry and Biology*, Vol. 86, Chipot, C.; Pohorille, A.; Eds. Berlin: Springer-Verlag; **2007**, 33–75.